$494 Million is the total value of Ghost Tree Capital, LLC's 53 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
INCY | New | INCYTE CORPput | $83,330,000 | – | 8,333 | +100.0% | 16.86% | – |
ECYT | New | ENDOCYTE INC | $19,998,000 | – | 2,200,000 | +100.0% | 4.05% | – |
SRPT | New | SAREPTA THERAPEUTICS INC | $17,411,000 | – | 235,000 | +100.0% | 3.52% | – |
IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $16,900,000 | – | 1,000,000 | +100.0% | 3.42% | – |
RCKT | New | ROCKET PHARMACEUTICALS INC | $15,938,000 | – | 850,000 | +100.0% | 3.22% | – |
CBIO | New | CATALYST BIOSCIENCES INC | $11,610,000 | – | 450,000 | +100.0% | 2.35% | – |
FOLD | New | AMICUS THERAPEUTICS INC | $11,280,000 | – | 750,000 | +100.0% | 2.28% | – |
MNTA | New | MOMENTA PHARMACEUTICALS INC | $9,075,000 | – | 500,000 | +100.0% | 1.84% | – |
ACAD | New | ACADIA PHARMACEUTICALS INC | $8,988,000 | – | 400,000 | +100.0% | 1.82% | – |
CNCE | New | CONCERT PHARMACEUTICALS INC | $8,015,000 | – | 350,000 | +100.0% | 1.62% | – |
ADMS | New | ADAMAS PHARMACEUTICALS INC | $7,766,000 | – | 325,000 | +100.0% | 1.57% | – |
ASMB | New | ASSEMBLY BIOSCIENCES INC | $7,371,000 | – | 150,000 | +100.0% | 1.49% | – |
RTRX | New | RETROPHIN INC | $7,029,000 | – | 314,367 | +100.0% | 1.42% | – |
AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $6,197,000 | – | 850,000 | +100.0% | 1.25% | – |
ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $5,768,000 | – | 800,000 | +100.0% | 1.17% | – |
GTHX | New | G1 THERAPEUTICS INC | $5,558,000 | – | 150,000 | +100.0% | 1.12% | – |
PTCT | New | PTC THERAPEUTICS INC | $5,412,000 | – | 200,000 | +100.0% | 1.10% | – |
ADRO | New | ADURO BIOTECH INC | $4,650,000 | – | 500,000 | +100.0% | 0.94% | – |
FXF | New | CURRENCYSHARES SWISS FRANC Tswiss franc sh | $4,507,000 | – | 45,800 | +100.0% | 0.91% | – |
MRSN | New | MERSANA THERAPEUTICS INC | $4,388,000 | – | 278,244 | +100.0% | 0.89% | – |
TGTX | New | TG THERAPEUTICS INC | $4,260,000 | – | 300,000 | +100.0% | 0.86% | – |
GLYC | New | GLYCOMIMETICS INC | $4,058,000 | – | 250,000 | +100.0% | 0.82% | – |
LCI | New | LANNET INC | $4,013,000 | – | 250,000 | +100.0% | 0.81% | – |
INFI | New | INFINITY PHARMACEUTICALS INC | $3,675,000 | – | 1,750,000 | +100.0% | 0.74% | – |
TSRO | New | TESARO INC | $3,537,000 | – | 61,900 | +100.0% | 0.72% | – |
SLDB | New | SOLID BIOSCIENCES INC | $2,888,000 | – | 385,000 | +100.0% | 0.58% | – |
JNCE | New | JOUNCE THERAPEUTICS INC | $2,796,000 | – | 125,092 | +100.0% | 0.57% | – |
BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lcall | $1,935,000 | – | 75,100 | +100.0% | 0.39% | – |
KPTI | New | KARYOPHARM THERAPEUTICS INC | $1,030,000 | – | 76,786 | +100.0% | 0.21% | – |
ANAB | New | ANAPTYSBIO INC | $937,000 | – | 9,000 | +100.0% | 0.19% | – |
MOTS | New | MOTUS GI HLDGS INC | $448,000 | – | 100,000 | +100.0% | 0.09% | – |
IMGN | New | IMMUNOGEN INC | $225,000 | – | 7,500 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
SPDR SER TR | 20 | Q3 2022 | 16.9% |
IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-16 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.